SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No._____1______)*
Indevus Pharmaceuticals, Inc.
-----------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
-------------------------------------------------------------
(Title of Class of Securities)
454072109
-----------------------------------------------------
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[XX] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6 pages
CUSIP No. 454072109 13G Page 2 of 6 Pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J. Morton Davis
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 412,081
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 412,081
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
412,081
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
.89%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 454072109 13G Page 3 of 6 Pages
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
D.H. Blair Investment Banking Corp.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 303,325
BENEFICIALLY --------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 303,325
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
303,325
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
.67%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO.
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
Page 4 of 6 Pages
Item 1.
(a) Name of Issuer:
Indevus Pharmaceuticals, Inc.
(b) Address of Issuer's Principal Executive Offices:
One Ledgemont Center
99 Hayden Avenue
Lexington, MA 02421
Item 2.
(a) Name of Person Filing:
J. Morton Davis and D.H. Blair Investment Banking Corp.
("Blair Investment") (together, the "Reporting Parties").
(b) Address of Principal Business Office or, if None, Residence:
The Reporting Parties' business address is 44 Wall Street,
New York, NY 10005.
(c) Citizen:
Mr. Davis is a United States citizen. Blair Investment is
incorporated in the State of Delaware.
(d) Title of Class of Securities:
Common Stock, $.001 par value ("shares").
(e) CUSIP#:
454072109
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), check whether the person filing is a:
(a) [X] Broker or Dealer registered under Section 15 of the
Act
(b) [ ] Bank as defined in section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in section 3(a)(19) of
the Act
(d) [ ] Investment Company registered under section 8 of the
Investment Company Act of 1940
(e) [ ] An investment adviser in accordance with 240.13d-1
(b)(1)(ii)(E)
(f) [ ] An employee benefit Plan or endowment fund in
accordance with 240.13d-1(b)(1)(ii)(F)
(g) [ ] A parent holding Company or control person in
accordance with 240.13d-1(b)(1)(ii)(G)
(h) [ ] A savings associations as defined in Section 3(b) of
the Federal Deposit Insurance Act
(i) [ ] A church plan that is excluded from definition of an
investment company under section 3(c)(14) of the
Investment Company Act of 1940.
Page 5 of 6 Pages
Item 4. Ownership:
(a)(b) As of October 7, 2002, Mr. Davis may be deemed to beneficially
own 412,081 shares or .89% of the Issuer's shares issued and
outstanding as follows: (i) 50,156 shares owned directly by Mr.
Davis, (ii) 303,325 shares owned directly by Blair Investment,
and (iii) 58,600 shares owned directly by Rosalind Davidowitz
(1).
As of October 7, 2002, Blair Investment may be deemed to
beneficially own 303,325 shares or .67% of the Issuer's shares
issued and outstanding as indicated in (ii) above.
(c) Mr. Davis has sole power to vote or to direct the vote, to
dispose or to direct the disposition of those shares owned by
Blair Investment. Rosalind Davidowitz has sole voting and
dispositive power over those shares owned directly by her.
Item 5. Ownership of Five Percent or Less of a Class:
The Reporting Parties own less than 5% of the outstanidng
shares.
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company:
Not applicable
Item 8. Identification and Classification of Members of the Group:
Not applicable.
Item 9. Notice of Dissolution of Group:
Not applicable.
_______________________________________________________________________________
(1) Rosalind Davidowitz is Mr. Davis' wife. Filing of this statement shall
not be deemed an admission by J. Morton Davis that he beneficially owns the
securities attributed to Rosalind Davidowitz for any purpose. J. Morton Davis
expressly disclaims beneficial ownership of all securities held by Rosalind
Davidowitz for any purpose.
Page 6 of 6 Pages
Item 10. Certification: By signing below we certify that to the best of our
knowledge and belief, the securities referred to above were
acquired in the ordinary course of business and were not acquired
and are not held for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities
and were not acquired and are not held in connection with or as
participant in any transaction having such purpose of effect.
SIGNATURES
After reasonable inquiry and to the best knowledge and belief of the
Reporting Persons, each such person or entity certifies that the information set
forth in this statement is true, complete and correct.
/s/ J. Morton Davis
Dated: October 7, 2002 By:________________________________
New York, New York J. Morton Davis
D.H. Blair Investment Banking Corp.
/s/ J. Morton Davis
Dated: October 7, 2002 By:________________________________
New York, New York J. Morton Davis
Chairman